BACKGROUND: Folate and other one-carbon metabolism nutrients may influence prostate cancer pathogenesis. Prior studies of these nutrients in relation to prostate cancer incidence have been inconclusive, and none have explored prostate cancer survival. OBJECTIVE: The objective was to assess whether dietary intakes of folate, riboflavin, vitamin B-6, vitamin B-12, and methionine measured around the time of prostate cancer diagnosis are associated with prostate cancer survival. DESIGN: This population-based prospective study comprised 525 men from Orebro, Sweden, who received a diagnosis of incident prostate cancer between 1989 and 1994 and completed a self-administered food-frequency questionnaire. Record linkages to the Swedish Death Registry enabled all cases to be followed for up to 20 y after diagnosis, and the cause of death was assigned via medical record review. Cox proportional hazards regression was used to calculate multivariable hazard ratios (HRs) and 95% CIs. During a median of 6.4 y of follow-up, 218 men (42%) died of prostate cancer and 257 (49%) of other causes. RESULTS: A comparison of the highest with the lowest quartile showed that vitamin B-6 intake was inversely associated with prostate cancer-specific death (HR: 0.71; 95% CI: 0.46, 1.10; P for trend = 0.08), especially in men with a diagnosis of localized-stage disease (HR; 0.05; 95% CI: 0.01, 0.26; P for trend = 0.0003). However, vitamin B-6 intake was not associated with improved prostate cancer survival among advanced-stage cases (HR: 1.04; 95% CI: 0.64, 1.72; P for trend = 0.87). Folate, riboflavin, vitamin B-12, and methionine intakes were not associated with prostate cancer survival. CONCLUSION: A high vitamin B-6 intake may improve prostate cancer survival among men with a diagnosis of localized-stage disease.
BACKGROUND:Folate and other one-carbon metabolism nutrients may influence prostate cancer pathogenesis. Prior studies of these nutrients in relation to prostate cancer incidence have been inconclusive, and none have explored prostate cancer survival. OBJECTIVE: The objective was to assess whether dietary intakes of folate, riboflavin, vitamin B-6, vitamin B-12, and methionine measured around the time of prostate cancer diagnosis are associated with prostate cancer survival. DESIGN: This population-based prospective study comprised 525 men from Orebro, Sweden, who received a diagnosis of incident prostate cancer between 1989 and 1994 and completed a self-administered food-frequency questionnaire. Record linkages to the Swedish Death Registry enabled all cases to be followed for up to 20 y after diagnosis, and the cause of death was assigned via medical record review. Cox proportional hazards regression was used to calculate multivariable hazard ratios (HRs) and 95% CIs. During a median of 6.4 y of follow-up, 218 men (42%) died of prostate cancer and 257 (49%) of other causes. RESULTS: A comparison of the highest with the lowest quartile showed that vitamin B-6 intake was inversely associated with prostate cancer-specific death (HR: 0.71; 95% CI: 0.46, 1.10; P for trend = 0.08), especially in men with a diagnosis of localized-stage disease (HR; 0.05; 95% CI: 0.01, 0.26; P for trend = 0.0003). However, vitamin B-6 intake was not associated with improved prostate cancer survival among advanced-stage cases (HR: 1.04; 95% CI: 0.64, 1.72; P for trend = 0.87). Folate, riboflavin, vitamin B-12, and methionine intakes were not associated with prostate cancer survival. CONCLUSION: A high vitamin B-6 intake may improve prostate cancer survival among men with a diagnosis of localized-stage disease.
Authors: S O Andersson; J Baron; R Bergström; C Lindgren; A Wolk; H O Adami Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-07 Impact factor: 4.254
Authors: Simon M Collin; Chris Metcalfe; Helga Refsum; Sarah J Lewis; Luisa Zuccolo; George Davey Smith; Lina Chen; Ross Harris; Michael Davis; Gemma Marsden; Carole Johnston; J Athene Lane; Marta Ebbing; Kaare Harald Bønaa; Ottar Nygård; Per Magne Ueland; Maria V Grau; John A Baron; Jenny L Donovan; David E Neal; Freddie C Hamdy; A David Smith; Richard M Martin Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: Yuan Ji; Kendra K S Nordgren; Yubo Chai; Scott J Hebbring; Gregory D Jenkins; Ryan P Abo; Yi Peng; Linda L Pelleymounter; Irene Moon; Bruce W Eckloff; Xiaoshan Chai; Jianping Zhang; Brooke L Fridley; Vivien C Yee; Eric D Wieben; Richard M Weinshilboum Journal: Drug Metab Dispos Date: 2012-07-17 Impact factor: 3.922
Authors: Mara M Epstein; Julie L Kasperzyk; Ove Andrén; Edward L Giovannucci; Alicja Wolk; Niclas Håkansson; Swen-Olof Andersson; Jan-Erik Johansson; Katja Fall; Lorelei A Mucci Journal: Am J Clin Nutr Date: 2011-01-12 Impact factor: 7.045
Authors: Mara M Epstein; Julie L Kasperzyk; Lorelei A Mucci; Edward Giovannucci; Alkes Price; Alicja Wolk; Niclas Håkansson; Katja Fall; Swen-Olof Andersson; Ove Andrén Journal: Am J Epidemiol Date: 2012-07-10 Impact factor: 4.897
Authors: Jeffrey J Tomaszewski; Erin L Richman; Natalia Sadetsky; Denise S O'Keefe; Peter R Carroll; Benjamin J Davies; June M Chan Journal: J Urol Date: 2013-10-03 Impact factor: 7.450
Authors: Alison J Price; Ruth C Travis; Paul N Appleby; Demetrius Albanes; Aurelio Barricarte Gurrea; Tone Bjørge; H Bas Bueno-de-Mesquita; Chu Chen; Jenny Donovan; Randi Gislefoss; Gary Goodman; Marc Gunter; Freddie C Hamdy; Mattias Johansson; Irena B King; Tilman Kühn; Satu Männistö; Richard M Martin; Klaus Meyer; David E Neal; Marian L Neuhouser; Ottar Nygård; Par Stattin; Grethe S Tell; Antonia Trichopoulou; Rosario Tumino; Per Magne Ueland; Arve Ulvik; Stefan de Vogel; Stein Emil Vollset; Stephanie J Weinstein; Timothy J Key; Naomi E Allen Journal: Eur Urol Date: 2016-04-06 Impact factor: 20.096